The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Carey Stephen P. | SVP & CFO | Option exercise(M) | 3K | $49.51 | $164K |
| Jul 2, 2026 | Carey Stephen P. | SVP & CFO | Sell(S) | 3K | $86.00 | $285K |
| Jul 2, 2026 | Carey Stephen P. | SVP & CFO | Option exercise(M) | 3K | $49.51 | $164K |
| Jun 29, 2026 | Carey Stephen P. | SVP & CFO | Sell(S) | 3K | $84.12 | $240K |
| Jun 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 500 | $82.03 | $41K |
| Jun 8, 2026 | Haughey Thomas | Director | Sell(S) | 2K | $80.88 | $162K |
| Jun 5, 2026 | Carey Stephen P. | SVP & CFO | Option exercise(M) | 3K | $49.51 | $164K |
| Jun 5, 2026 | Carey Stephen P. | SVP & CFO | Sell(S) | 3K | $80.00 | $265K |
| Jun 5, 2026 | Carey Stephen P. | SVP & CFO | Option exercise(M) | 3K | $49.51 | $164K |
| May 21, 2026 | Haughey Thomas | Director | Grant(A) | 4K | — | $0 |
| May 21, 2026 | Tannenbaum Renee P | Director | Grant(A) | 4K | — | $0 |
| May 21, 2026 | Pera Antonio R | Director | Grant(A) | 4K | — | $0 |
| May 21, 2026 | Leonard Matthew J | Director | Grant(A) | 4K | — | $0 |
| May 21, 2026 | Thoma Jeanne | Director | Grant(A) | 4K | — | $0 |
| May 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 500 | $78.16 | $39K |
| May 13, 2026 | Walsh Patrick D | Director | Sell(S) | 10K | $80.63 | $806K |
| May 12, 2026 | Gutwerg Ori | SVP, GENERICS | Sell(S) | 3K | $79.50 | $220K |
| May 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell(S) | 459 | $79.21 | $36K |
| May 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Sell(S) | 55K | $77.57 | $4.3M |
| May 11, 2026 | Walsh Patrick D | Director | Sell(S) | 4K | $80.75 | $321K |
| Apr 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 500 | $77.95 | $39K |
| Mar 13, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell(S) | 3K | $71.64 | $227K |
| Mar 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 500 | $72.62 | $36K |
| Mar 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell(S) | 5K | $74.91 | $357K |
| Mar 9, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell(S) | 4K | $74.18 | $267K |
| Mar 9, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell(S) | 5K | $74.13 | $377K |
| Mar 7, 2026 | Carey Stephen P. | SVP & CFO | Tax withholding(F) | 5K | $74.04 | $381K |
| Mar 7, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Tax withholding(F) | 17K | $74.04 | $1.3M |
| Mar 7, 2026 | Gutwerg Ori | SVP, GENERICS | Tax withholding(F) | 3K | $74.04 | $245K |
| Mar 7, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding(F) | 3K | $74.04 | $245K |
| Mar 6, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell(S) | 2K | $74.22 | $157K |
| Mar 6, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell(S) | 1K | $75.00 | $111K |
| Mar 5, 2026 | Carey Stephen P. | SVP & CFO | Sell(S) | 4K | $75.56 | $302K |
| Mar 5, 2026 | Carey Stephen P. | SVP & CFO | Option exercise(M) | 3K | $49.51 | $164K |
| Mar 5, 2026 | Carey Stephen P. | SVP & CFO | Sell(S) | 3K | $75.42 | $250K |
| Mar 5, 2026 | Carey Stephen P. | SVP & CFO | Option exercise(M) | 3K | $49.51 | $164K |
| Mar 3, 2026 | Walsh Patrick D | Director | Sell(S) | 6K | $74.23 | $445K |
| Mar 3, 2026 | Gutwerg Ori | SVP, GENERICS | Sell(S) | 2K | $76.50 | $158K |
| Mar 2, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell(S) | 417 | $74.00 | $31K |
| Feb 28, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding(F) | 628 | $73.90 | $46K |
| Feb 28, 2026 | Carey Stephen P. | SVP & CFO | Tax withholding(F) | 3K | $73.90 | $205K |
| Feb 28, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Tax withholding(F) | 12K | $73.90 | $903K |
| Feb 28, 2026 | Gutwerg Ori | SVP, GENERICS | Tax withholding(F) | 2K | $73.90 | $164K |
| Feb 28, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding(F) | 2K | $73.90 | $164K |
| Feb 28, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding(F) | 2K | $73.90 | $164K |
| Feb 28, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding(F) | 2K | $73.90 | $115K |
| Feb 28, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding(F) | 2K | $73.90 | $115K |
| Feb 26, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Grant(A) | 6K | $77.15 | $465K |
| Feb 26, 2026 | Carey Stephen P. | SVP & CFO | Grant(A) | 22K | $77.15 | $1.7M |
| Feb 26, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Grant(A) | 76K | $77.15 | $5.8M |
| Feb 26, 2026 | Gutwerg Ori | SVP, GENERICS | Grant(A) | 13K | $77.15 | $1.0M |
| Feb 26, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Grant(A) | 21K | $77.15 | $1.6M |
| Feb 26, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS, Director | Grant(A) | 11K | $77.15 | $858K |
| Feb 26, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Grant(A) | 11K | $77.15 | $858K |
| Feb 26, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Grant(A) | 14K | $77.15 | $1.1M |
| Feb 26, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Grant(A) | 11K | $77.15 | $834K |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell(S) | 5K | $78.02 | $415K |
| Feb 20, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell(S) | 2K | $77.99 | $135K |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell(S) | 2K | $77.53 | $162K |
| Feb 14, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding(F) | 485 | $77.36 | $38K |
| Feb 14, 2026 | Carey Stephen P. | SVP & CFO | Tax withholding(F) | 2K | $77.36 | $189K |
| Feb 14, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Tax withholding(F) | 10K | $77.36 | $797K |
| Feb 14, 2026 | Gutwerg Ori | SVP, GENERICS | Tax withholding(F) | 2K | $77.36 | $146K |
| Feb 14, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding(F) | 2K | $77.36 | $186K |
| Feb 14, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding(F) | 2K | $77.36 | $133K |
| Feb 14, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding(F) | 2K | $77.36 | $138K |
| Feb 14, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding(F) | 1K | $77.36 | $100K |
| Feb 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 500 | $76.80 | $38K |
| Feb 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding(F) | 566 | $76.70 | $43K |
| Feb 12, 2026 | Carey Stephen P. | SVP & CFO | Tax withholding(F) | 3K | $76.70 | $217K |
| Feb 12, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Tax withholding(F) | 12K | $76.70 | $896K |
| Feb 12, 2026 | Gutwerg Ori | SVP, GENERICS | Tax withholding(F) | 2K | $76.70 | $136K |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell(S) | 7K | $76.55 | $538K |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding(F) | 3K | $76.70 | $243K |
| Feb 12, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding(F) | 2K | $76.70 | $123K |
| Feb 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding(F) | 2K | $76.70 | $118K |
| Feb 12, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding(F) | 1K | $76.70 | $91K |
| Feb 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding(F) | 2K | $76.25 | $134K |
| Feb 11, 2026 | Carey Stephen P. | SVP & CFO | Tax withholding(F) | 6K | $76.25 | $420K |
| Feb 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO, Director | Tax withholding(F) | 31K | $76.25 | $2.3M |
| Feb 11, 2026 | Gutwerg Ori | SVP, GENERICS | Tax withholding(F) | 4K | $76.25 | $325K |
| Feb 11, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding(F) | 5K | $76.25 | $347K |
| Feb 11, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS, Director | Tax withholding(F) | 3K | $76.25 | $221K |
| Feb 11, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding(F) | 4K | $76.25 | $326K |
| Feb 11, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding(F) | 3K | $76.25 | $230K |
| Feb 11, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding(F) | 3K | $76.25 | $230K |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 500 | $84.33 | $42K |
| Dec 18, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell(S) | 2K | $82.40 | $134K |
| Dec 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 400 | $82.32 | $33K |
| Dec 5, 2025 | Tannenbaum Renee P | Director | Sell(S) | 2K | $81.15 | $146K |
| Nov 13, 2025 | Walsh Patrick D | Director | Gift(G) | 3K | — | $0 |
| Nov 13, 2025 | Walsh Patrick D | Director | Sell(S) | 9K | $86.88 | $751K |
| Nov 13, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell(S) | 94 | $88.00 | $8K |
| Nov 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 400 | $87.27 | $35K |
| Nov 12, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell(S) | 15K | $89.07 | $1.3M |
| Oct 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 400 | $90.09 | $36K |
| Sep 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell(S) | 1K | $98.04 | $98K |
| Sep 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell(S) | 400 | $98.42 | $39K |
| Sep 12, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding(F) | 2K | $97.71 | $167K |
| Sep 3, 2025 | Pera Antonio R | Director | Sell(S) | 7K | $94.94 | $692K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).